| Catalog Number | A000450 |
| CAS Number | 53123-88-9 |
| Molecular Formula | C51H79NO13
|
| Purity | 95% |
| Target | mTOR |
| Solubility | >45.7mg/mL in DMSO |
| Storage | Desiccate at -20°C |
| Overview of Clinical Research | <span style=”font-family:arial,helvetica,sans-serif;”><span style=”color:#000000;”><span style=”font-size:12px;”>Rapamycin is a <span style=”caret-color: rgb(102, 102, 102); orphans: 2; widows: 2;”>MTOR protein inhibitor and a T lymphocyte inhibitor. It receives the orphan drug status in </span><span style=”font-variant-ligatures: normal; orphans: 2; widows: 2;”>Lymphangioleiomyomatosis and Fibroma. The </span><span style=”font-variant-ligatures: normal; orphans: 2; widows: 2;”>Phase-III clinical trials in Neurofibromatosis 1 (In adults, In children, In the elderly) in Japan (unspecified route) (NCT04461886) started in 2020.</span></span></span></span>
|
| IUPAC Name | (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone |
| InChI | InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44 |
| InChIKey | QFJCIRLUMZQUOT-HPLJOQBZSA-N |
| SMILES | CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)O)C)C)O)OC)C)C)C)OC |
| Reference | <br />
1:[Response to everolimus in patients with giant cell astrocytoma associated to tuberous sclerosis complex]. Mateos-González ME, López-Laso E, Vicente-Rueda J, Camino-León R, Fernández-Ramos JA, Baena-Gómez MA, Peña-Rosa MJ.Rev Neurol. 2014 Dec 1;59(11):497-502. Spanish. PMID: 25418144 Free Article<br />
2:[Therapeutic possibilities in refractory epilepsy in tuberous sclerosis complex]. Puertas-Martin V, Carreras-Saez I, Marana A, Ruiz-Falco Rojas ML, Cantarin-Extremera V, Calleja-Gero ML.Rev Neurol. 2014 Jun 16;58(12):529-35. Spanish. PMID: 24915028 Free Article<br />
3:Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation. Peddi VR, Wiseman A, Chavin K, Slakey D.Transplant Rev (Orlando). 2013 Oct;27(4):97-107. doi: 10.1016/j.trre.2013.06.001. Epub 2013 Aug 8. Review. PMID: 23932018<br />
4:Neuroendocrine tumors: treatment updates. Khagi S, Saif MW.JOP. 2013 Jul 10;14(4):367-71. doi: 10.6092/1590-8577/1657. PMID: 23846929 Free Article<br />
5:The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). Schampaert E, Cohen EA, Schlüter M, Reeves F, Traboulsi M, Title LM, Kuntz RE, Popma JJ; C-SIRIUS Investigators..J Am Coll Cardiol. 2004 Mar 17;43(6):1110-5. PMID: 15028375 Free Article
|
